The unaudited consolidated financial statements of Brooks Automation, Inc. and its subsidiaries (“Brooks”, or the “Company”) included herein have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP").
The accompanying Consolidated Balance Sheet as of September 30, 2017 was derived from the audited annual consolidated financial statements as of the period then ended.
Net foreign currency transaction and remeasurement losses totaled $2.0 million and $0.5 million, respectively, during the three months ended December 31, 2017 and 2016.
Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts.
As of December 31, 2017, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis using Level 3 inputs.
In March 2016, the FASB issued an amendment to the accounting guidance to simplify accounting for share-based payment awards issued to employees.
Additionally, the entity can make an accounting policy election to either estimate the number of awards that are expected to vest, consistent with the current accounting guidance, or account for forfeitures as they occur.
In March 2016, the FASB issued an amendment to the accounting guidance to simplify accounting for embedded derivatives.
An entity performing the assessment in accordance with this guidance is required to assess the embedded call (put) options solely in accordance with the four-step decision process set forth in the guidance.
In February 2016, the FASB issued new accounting guidance for reporting lease transactions.·    Overview.
This section provides an analysis of our financial results for the three months ended December 31, 2017 compared to the three months ended December 31, 2016.
We are a leading global provider of automation and cryogenic solutions for multiple applications and markets.
We primarily serve the semiconductor capital equipment market and sample management market for life sciences.
Over the past several years, we have acquired and developed essential capabilities required to strategically address the sample management needs across multiple end markets within the life sciences industry.
Please refer to Note 4, “Acquisitions” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10‑Q for further information on this transaction.
Results of Operations- Revenue for the three months ended December 31, 2017 increased to $189.3 million, or by 18%, as compared to the corresponding period of the prior fiscal year.
Operating expenses were $54.4 million during the first quarter of fiscal year 2018 as compared to $43.8 million during the first quarter of fiscal year 2017, an increase of $10.6 million.